The clinical trial by Kremer et al. [4] , while similar in design 3.
to the study by Tanaka et al. [2] in phase (phase 2), tofacitinib doses studied, and the requirement for inadequate response to stable background methotrexate, showed the lowest treatment eff ect size for tofacitinib of all the studies of tofacitinib in RA conducted to date. Therefore, comparison to the results of this study is not representative of comparison to the larger body of evidence demonstrating the eff ect size of tofacitinib. We cannot explain the variation in eff ect size by study on a quantitative basis, and believe that our descriptive and non-quantitative observation that the response rates were higher in the Tanaka study remains the most appropriate.
While adherent with the Pharmaceutical Aff airs Law and relevant self-regulations, and originally intended to present the development program results in chronological order, Pfi zer understands how the appearance of the fi gure in the Specifying Product Information Summaries or commercial bulletins describing the study by Tanaka et al. fi rst has a potential risk to elicit misunderstanding among health care professionals, who may assume this is a phase 3 study that represents the effi cacy observed in the global development program. Thus, Pfi zer has decided to change the order of clinical results by presenting confi rmatory phase 3 results fi rst followed by other clinical results including those from this phase 2 study. Pfi zer Japan is committed to the appropriate promotion of tofacitinib and the accurate presentation of the effi cacy and safety profi le of tofacitinib by our company representatives.
Finally, we agree with Dr. Minota that the results of the postmarketing surveillance (PMS) are important. Pfi zer is strongly committed to conduct the PMS with all case registration to investigate and publish the long-term safety and effi cacy profi le of tofacitinib in Japanese RA patients in a real-world setting.
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In Response:
We thank Dr. Seiji Minota for his thought-provoking comments on the article [1] as well as questions on the inclusion of the American College of Rheumatology 20% improvement criteria (ACR20) response rates in tofacitinib promotional materials.
The tofacitinib clinical trial (NCT00603512) by Tanaka et al. [2] was conducted in phase 2 to explore the possibility of enrolling Japanese patients with rheumatoid arthritis (RA) in the phase 3 multiregional clinical trial (NCT00847613), which was reported by van der Heijde et al. [3] A target sample size of 125 patients (5 treatment groups of 25 patients per group) was required to provide at least 80% power and a 5% signifi cance level, one-sided testing, to detect a trend of dose -response using the Cochran -Armitage trend test on ACR20 response rates. The Cochran -Armitage test was highly positive ( p Ͻ 0.0001) and the ACR20 response rates, as calculated by last observation carried forward (LOCF), are as quoted in Dr. Minota ' s letter [1] . However, while the odds ratio for ACR20 responses on tofacitinib 5 mg twice daily compared with those on placebo described in Dr. Minota ' s letter [1] was calculated correctly, we have several concerns with his contextualization of the odds ratio:
Any interpretation of this odds ratio is severely limited by the 1.
small size of the trial and the resulting wide range of its 95% confi dence limits (16.3, 1495.6). The clinical trial by Kremer et al. [4] , to which these results are 2.
compared, reported primary effi cacy results at week 12 based on non-responder imputation (NRI), not LOCF. The ACR20 response rates on tofacitinib 5 mg twice daily in the Kremer study when calculated at week 12 by LOCF are higher, 62.0%, than those calculated by NRI, 50.7%, and the corresponding odds ratio for ACR20 responses calculated by LOCF is slightly larger, 2.7 (95% confi dence limits: 1.36 and 5.34).
